not tagged
astrazeneca,daiichi sankyo,anzup
['breast', 'evolution', 'enhertu', 'fierce']
enhertu's historic her2-low breast cancer data also sparked talks of the need for a her2 diagnostic revolution. #asco22 
Tweets from the Fierce Life Sciences editorial team